News

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

A new study found a greater sleep apnea risk was linked to verbal episodic memory decline and worse sleep quality was linked to executive function decline.

Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

A large language model demonstrated comparative diagnostic accuracy and completeness in glaucoma and retina disease to fellowship-trained ophthalmologists.

Of those who received an infliximab biosimilar, 87.8% were maintained on a single biosimilar without the need to switch to an alternative product.

Worse examination-based and self-reported vision impairment was associated with depressive and anxiety symptoms among adults aged ≥65 years.

These findings, to be presented at AAAAI, may help to expand upon clinicians’ awareness of the mechanics of air pollution’s effect on asthma.

The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

A new study found patients with Parkinson’s disease have a lower daytime light exposure with a mean light intensity of 201.1 lux than controls with a light intensity of 337.7 lux.

All patients who received an HCV+ organ achieved SVR12 and had lower rates of rejection and chronic lung allograft dysfunction compared to uninfected donor organ recipients.

This analysis, to be presented at AAAAI, suggests that adolescents’ attendance of daycare may lead to decreased IgE levels and diminished food and aeroallergen sensitization rates.

A new study found gender inequality, poor work-life balance, a lack of workplace autonomy, and caregiving responsibilities contribute to women in healthcare professions having more stress than their male colleagues.

Zhang discusses the consequences of stigmatizing language for substance use disorders and reasons gastroenterologists and hepatologists may be falling behind.

Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.

Patients with gout and negative DECTs for monosodium urate crystal deposition exhibited milder disease and a lower comorbidity burden.

Among patients aged 40 – 49 years, asymptomatic hyperuricemia was linked to incident arthritis.

Often considered a cause of symptom onset in musculoskeletal conditions, a new study found that weather factors do not appear to be a risk factor for pain.

These data contribute to existing research into links observed between rheumatic diseases such as gout and cardiovascular disease among Indigenous North American populations.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

Interactions with alcohol consumption were identified at ADH1B and MLXIPL for association with serum urate level and at ADH1B for association with hyperuricemia and gout

A new study found the odds of gout were 2.65 times greater in patients with OSA than in patients without OSA.

A recent study points to a link between bisphenol exposure and elevated uric acid levels, with implications for gout risk, especially in women.

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.